SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > Ingredients

breaking news - update

BASF sees synergies between new acquisition Pronova and Equateq

By Gareth MacDonald+

21-Jan-2013
Last updated on 21-Jan-2013 at 10:41 GMT

BASF wins over Pronova shareholders
BASF wins over Pronova shareholders

BASF has had its offer for omega-3 API maker Pronova Biopharma accepted by 97.7 per cent of the Norwiegan firm’s shareholders.

The deal – which will see the German firm pay around €684m for Pronova – was finally accepted last week after a bidding process that saw the German chemicals firm increase its offer in response to resistance from minority shareholders.

A BASF spokesman told in-Pharmatechnologist.com today that: “We are confident that this is a good investment.

This acquisition will create numerous synergies by combining BASF’s global customer reach and many years of experience with Pronova’s solid know-how and scientific expertise in the production of highly concentrated omega-3 fatty acids, with the technology portfolio of Equateq [now operating under the name BASF Pharma Callanish].”

He explained that the aim of the deal was to strengthen BASF’s portfolio and expand its position in the research and development and manufacturing of omega-3 fatty acids for pharmaceutical and consumer health products.

BASF will have an attractive technology portfolio for developing and manufacturing omega-3 fatty acids. Highly concentrated omega-3 fatty acids are a globally growing market, driven by an increasing consumer awareness of omega-3 fatty acid health benefits.”  

Pronova supplies GSK with the active pharmaceutical ingredient (API) for its heart pill Lovaza. BASF’s other omega-3 business – BASF Pharma Callanish -  is one of the firm’s for which Amarin is seeking US Food and Drug Administration (FDA) approval as a supplier for its rival product Vascepa .

Fatty acid synergies

Pronova gives BASF capacity. The firm operates two production facilities – one in Norway and one in Denmark – which are capable of producing 2,500 tons of pharmaceutical grade omega-3 a year and employs around 311 people.

This contrasts with BASF Callanish, which has a single production facility on the Isle of Lewis in Scotland .

The technology 'synergies' mentioned above are likely to involve the proprietary chromatographic separation methods in place at Callanish that - according to BASF - allow for more flexible blending and formulation of omega-3 fatty acids at exceptional purity levels.

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

Related products

Key Industry Events

 

Access all events listing

Our events, Events from partners...